Suppr超能文献

细胞游离重组人胶原蛋白支架植入四年后稳定的角膜再生。

Stable corneal regeneration four years after implantation of a cell-free recombinant human collagen scaffold.

机构信息

Integrative Regenerative Medicine Centre, Dept. of Clinical and Experimental Medicine, Cell Biology Bldg. - Level 10, Linköping University, SE-581 85 Linköping, Sweden.

Department of Ophthalmology, Maisonneuve-Rosemont Hospital, 5415 Boulevard de L'Assomption, Montreal, QC, H1T 2M4, Canada.

出版信息

Biomaterials. 2014 Mar;35(8):2420-7. doi: 10.1016/j.biomaterials.2013.11.079. Epub 2013 Dec 25.

Abstract

We developed cell-free implants, comprising carbodiimide crosslinked recombinant human collagen (RHC), to enable corneal regeneration by endogenous cell recruitment, to address the worldwide shortage of donor corneas. Patients were grafted with RHC implants. Over four years, the regenerated neo-corneas were stably integrated without rejection, without the long immunosuppression regime needed by donor cornea patients. There was no recruitment of inflammatory dendritic cells into the implant area, whereas, even with immunosuppression, donor cornea recipients showed dendritic cell migration into the central cornea and a rejection episode was observed. Regeneration as evidenced by continued nerve and stromal cell repopulation occurred over the four years to approximate the micro-architecture of healthy corneas. Histopathology of a regenerated, clear cornea from a regrafted patient showed normal corneal architecture. Donor human cornea grafted eyes had abnormally tortuous nerves and stromal cell death was found. Implanted patients had a 4-year average corrected visual acuity of 20/54 and gained more than 5 Snellen lines of vision on an eye chart. The visual acuity can be improved with more robust materials for better shape retention. Nevertheless, these RHC implants can achieve stable regeneration and therefore, represent a potentially safe alternative to donor organ transplantation.

摘要

我们开发了无细胞植入物,由碳化二亚胺交联的重组人胶原蛋白 (RHC) 组成,通过内源性细胞募集实现角膜再生,以解决全球供体角膜短缺的问题。患者接受了 RHC 植入物移植。四年多来,再生的新角膜稳定地整合在一起,没有排斥反应,也不需要供体角膜患者所需的长期免疫抑制治疗。植入物区域没有招募炎性树突状细胞,而即使进行免疫抑制治疗,供体角膜接受者的中央角膜也会出现树突状细胞迁移,并观察到排斥反应。四年中,随着神经和基质细胞的持续再殖,出现了再生,接近健康角膜的微观结构。从再次接受移植的患者的再生、透明角膜的组织病理学显示出正常的角膜结构。供体人角膜移植的眼睛神经异常扭曲,并且发现基质细胞死亡。植入患者的平均矫正视力为 4 年 20/54,在视力表上增加了超过 5 行的视力。通过使用更好的形状保持材料,可以提高视力。然而,这些 RHC 植入物可以实现稳定的再生,因此,代表了一种潜在的安全替代供体器官移植的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验